Discounted Cash Flow (DCF) Analysis Levered
Immix Biopharma, Inc. (IMMX)
$1.82
-0.08 (-4.21%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||
| Operating Cash Flow | - | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | ||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | ||||||||
| Free Cash Flow | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 1.82 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | 8.44 |
| Cost of Debt | |
| Tax Rate | -0.02 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.395 |
| Total Debt | - |
| Total Equity | 15.37 |
| Total Capital | 15.37 |
| Debt Weighting | 0.00 |
| Equity Weighting | 100.00 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| WACC | ||||||||
| PV LFCF | - | - | - | - | - | - | - | - |
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 3.40 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -17.64 |
| Equity Value | - |
| Shares Outstanding | 8.44 |
| Equity Value Per Share | - |